Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.35 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21972255 | 0.91 | LMNA (0.42) | LMNAPDGFRBKDM4ESLC16A3SLC16A1 | |
| SCHEMBL21972251 | 0.91 | LMNA (0.49) | LMNAPDGFRBKDM4ESLC16A3SLC16A1 | |
| SCHEMBL21972261 | 0.88 | LMNA (0.40) | LMNAPDGFRBKDM4ESLC16A3SLC16A1 | |
| SCHEMBL21972266 | 0.82 | LMNA (0.49) | LMNAPDGFRBKDM4EHTTMEN1 | |
| SCHEMBL20739438 | 0.82 | PDGFRB (0.57) | LMNAPDGFRBKDM4EHTTMEN1 | |
| SCHEMBL21971005 | 0.82 | LMNA (0.51) | LMNAPDGFRBKDM4EHTTMEN1 | |
| SCHEMBL21971004 | 0.80 | PDGFRB (0.53) | LMNAPDGFRBKDM4EHTTMEN1 | |
| SCHEMBL21972250 | 0.79 | PDGFRB (0.46) | LMNAPDGFRBKDM4EHTTMEN1 | |
| SCHEMBL21971001 | 0.79 | LMNA (0.51) | LMNAPDGFRBKDM4ESLC16A3SLC16A1 | |
| SCHEMBL21971404 | 0.79 | LMNA (0.58) | LMNAPDGFRBKDM4EHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046655-B2 | Compound and method for producing same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-20200140394-A1 | NOVEL COMPOUND AND METHOD FOR PRODUCING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140394-A1 | NOVEL COMPOUND AND METHOD FOR PRODUCING SAME | CBR3, NR2E3, NR5A2 | LMNA 4733/4885PDGFRB 2517/4885KDM4E 4526/4885 |
| US-11046655-B2 | Compound and method for producing same | CBR3, NR5A1, NR2E3 | LMNA 4570/4885PDGFRB 2499/4885KDM4E 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.